Evidence map›Paper›PMID 28017891›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy.

Ying Xie, Tracy Murray-Stewart, Yazhe Wang, Fei Yu, Jing Li, Laurence J Marton, Robert A Casero, David Oupický

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ying XieCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Tracy Murray-StewartThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Yazhe WangCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Fei YuCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Jing LiCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
Laurence J MartonDepartment of Laboratory Medicine, University of California, San Francisco, CA, United States.
Robert A CaseroThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, United States.
David OupickýCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address: david.oupicky@unmc.edu.
University of Nebraska Medical Center · USJohns Hopkins University · USNebraska Medical Center · USUniversity of California, San Francisco · US

Funding

Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention targetR01CA204345 · NCI · JOHNS HOPKINS UNIVERSITY · PI CASERO, ROBERT A., WOSTER, PATRICK M · 2016 to 2020
$3.4M
Multilayered redox-responsive nanoparticles for delivery of drug-siRNA combinatioR01EB015216 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2014 to 2017
$1.3M
Drug-based polycations for combination drug-gene deliveryR21EB014570 · NIBIB · WAYNE STATE UNIVERSITY · PI OUPICKY, DAVID · 2012 to 2013
$410k
NCI NIH HHS R01 CA204345NIBIB NIH HHS R01 EB015216NIBIB NIH HHS R21 EB014570
6 · The paper itself

Abstract

Combination of anticancer drugs with therapeutic microRNA (miRNA) has emerged as a promising anticancer strategy. However, the promise is hampered by a lack of desirable delivery systems. We report on the development of self-immolative nanoparticles capable of simultaneously delivering miR-34a mimic and targeting dysregulated polyamine metabolism in cancer. The nanoparticles were prepared from a biodegradable polycationic prodrug, named DSS-BEN, which was synthesized from a polyamine analog N

Indexed as

AnimalsAntineoplastic AgentsColonColorectal NeoplasmsDrug CarriersFemaleHCT116 CellsHumansMice, NudeMicroRNAsNanoparticlesPolyaminesRectumSpermineAntineoplastic AgentsDrug CarriersMicroRNAsN(1),N(11)-diethylnorsperminePolyaminesSpermineBisethylnorspermineCancerCombination deliverymiRNANanoparticlesPolyamine metabolismPolyplexesSelf-immolative polymer

Identifiers

PMID28017891
PMCPMC5258827
OpenAlexW2567632447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.